References
- 1. Ruilope Lm. Renal Function And Cardiovascular Risk In Hypertensive Patients. J Hypertension. 2005; 23(10): 1787-8.
- 2. Dyer Ar., Elliott P., Stamler Sr., Stamler J. Body Mass Index And Association Of Sodium And Potassium With Blood Pressure In Lntersalt . Hypertension. 1994; 23:729-6.
- 3. Nussinovitch U. The Heart In Rheumatic, Autoimmune And Inflammatory Disease Pathophysiology, Clinical Aspects And Therapeutic Approaches. Academic Press, 2017: 766.
- 4. Kovalyova O., Belovol A., Zayika M. The Role Of Oxidative Stress In Cardiovascular Disease. J Academy Of Medical Sciences Of Ukraine. 2005; 11(4): 660-70.
- 5. Kovalyova O., Ashcheulova T. Tumor Necrosis Factor-Α, Apoptosis In The Pathology Of Cardiovascular System. Original, Kharkiv, 2003: 95.
- 6. Kovalyova O., Ashcheulova T., Gerasimchuk N. Relationship Of Immune Activation And Oxidative Stress In Patients With Hypertension And Their Correction Combined Antihypertensive Therapy. Scientific Bulletin Belsu Medicine Pharmacy. 2015; 16 (213) Issue 31: 52-9.
- 7. Kovalyova O., Shapovalova S., Gerasimchuk N. Combination Therapy Of Hypertension. Pleiad, Kharkiv, 2005: 48.
- 8. Kovalenko V., Nesukay E., Yakovenko A. Problems Of Diagnosis And Management Of Patients With Metabolic Syndrome. Ukrain J Of Cardiology, 2006; 4: 98-105.
- 9. Sirenko Y. Dihydropyridine Calcium Channel Blockers - A New Provision To Reduce The Risk Of Complications Of Hypertension. J News Of Medicine And Pharmacy. 2009; 18 (292): 3-4.
- 10. Mancia G., Fagard R., Narkiewicz K., Et Al. 2013 Esh/Esc Guidelines For The Management Of Arterial Hypertension: The Task Force For The Management Of Arterial Hypertension Of The European Society Of Hypertension (Esh) And Of The European Society Of Cardiology (Esc). European Heart J. 2013; 34(28): 2159-2219.
- 11. World Health Organization. Obesity: Preventing And Managing The Global Epidemic. Who Technical Report Series. 2000: 1-252.
- 12. Kovalyova O., Ashcheulova T., Gerasimchuk N., Safargalina-Kornilova N. The Role Of Oxidative Stress In The Formation And Progression Of Hypertension. Scientific Bulletin Belsu Medicine Pharmacy. 2015; 4(201) Issue 29: 5-10.
- 13. Leonetti G., Magnani B., Rappelli A., Trimarco B., Zanchetti A. Et Al. Tolerability Of Long-Term Treatment With Lercanidipine Versus Amlodipine And Lacidipine In Elderly Hypertensives. Amer J Hypertension. 2002; 15(11): 932-940.
- 14. Chung O., Unger T. Angiotensin Ii Receptor Blockade And End Organ Protection. Amer J Hypertension. 1999; 12:150-156.
- 15. Ruiz-Ortega M., Lorenzo O., Suzuki Y., Rupérez M., Egido J. Proinflammatory Actions Of Anqiotensin П. Curr Opin Nephrol Hypertens. 2001; 10(3): 321-9.
- 16. Ashcheulova T. Comparative Characteristics Of The Clinical Efficacy Of Inhibitors Of The Renin-Angiotensin System In Hypertension: Impact On Biomarkers Of Systemic Inflammation. Medical Practice. 2007; 3:48-51.
- 17. Ambrosova T., Kovalyova O., Ashcheulova T. Therapeutic Potential Angiotensin Ii Receptor Antagonists In Patients With Arterial Hypertension With Metabolic Disorders: Effect On Carbohydrate And Lipid Profili. Ukrainian Therapeutical J. 2010; 4:17-22.
- 18. Shargorodsky M., Hass E., Boaz M., Gavish D., Zimlichman R. High Dose Treatment With Angiotensin Ii Receptor Blocker In Patients With Hypertension: Differential Effect Of Protection Versus Blood Pressure Lowering. J Atherosclerosis. 2008; 197(1): 303-310.
- 19. Mitchenko E.. Gulaya N., Viktorov A. Use Of Calcium Antagonists And No-State Change In Patients With Hypertension. Ukrain J Of Cardiology 2000; 1-2: 49-55.
- 20. Zhang X., Hintze T.H. Amlodipine Releases Nitric Oxide From Canine Coronary Microvessels: An Unexpected Mechanism Of Action Of A Calcium Channel-Blocking Agent. Circulation. 1998; 97(6): 576-580.
- 21. Black S.M., Fineman J.R., Steinhorn R.H., Bristow J., Soifer S.J. Increased Endothelial Nos In Lambs With Increased Pulmonary Blood Flow And Pulmonary Hypertension. Am J Physiol Soc.1998; 275(5): 1643-1651.
- 22. Taddei S., Virdis A., Ghiadoni L., Uleri S., Magagna A., Salvetti A. Lacidipine Restores Endotheliumdependent Vasodilation In Essential Hypertensive Patients. J Hypertension. 1997; 30(6): 1606-1612.
- 23. Krenek P., Salomone S., Kyselovic J., Wibo M., Morel N., Godfraind T. Lacidipine Prevents Endothelial Dysfunction In Salt Loaded Stroke Prone Hypertensive Rats. J Hypertension. 2001; 37: 1124-1128.
- 24. Svischenko E. Anti-Atherogenic Effect Of Lacidipine: Study Elsa (European Lacidipine Study On Atherosclerosis). Medicine Svіtu. 2002.
- 25. Herbette L.G. The Interaction Of Lacidipine With Biological Membranes: The Molecular Of Calcium Antagonists. Rev Contemp Pharmacother.1995; 6(1): 8.
- 26. Bernini F., Corsini A., Raiteri M., Soma M. R., Paoletti R. Effects Of Lacidipine On Experimental Models Of Atherosclerosis. J Of Hypertension. 1993; 11(Suppl 1): 61-66.
- 27. Soma M.R. Calcium Antagonists In Atherosclerosis: Focus On Lacidipine. Resesrch And Clinical Forums. 1994; 6(1): P. 543-551.
- 28. Godfraind T. Effect Of Calcium Antagonist In Preclinical Models Of Atherosclerosis. The Elsa Study Results. Adis. 2002; 6-7.